Results 91 to 100 of about 13,218 (206)

Virological Effectiveness of Dolutegravir Plus Darunavir in People with Multi-Drug-Resistant HIV: Data from the PRESTIGIO Registry

Viruses
Background: Data on the use of dolutegravir (DTG) plus boosted darunavir (DRV/b) in people with 4-class drug-resistant HIV (4DR-PWH) are limited. This study assessed the virological effectiveness of DTG + DRV/b in this population using real-world data ...
Filippo Lagi, Michele Bellomo, Riccardo Lolatto, Filippo Ducci, Seble Tekle Kiros, Vincenzo Spagnuolo, Rebecka Papaioannu Borjesson, Tommaso Clemente, Leonardo Calza, Marcello Feasi, Emanuele Focà, Andrea Giacomelli, Roberto Gulminetti, Barbara Menzaghi, Antonella Castagna, on behalf of the PRESTIGIO Study Group   +15 more
doaj   +1 more source

Use of darunavir in HIV-infected women during pregnancy

Терапевтический архив, 2013
The use of antiretroviral drugs (ARVDs) in a mother and a child can reduce the risk of vertical transmission of human immunodeficiency virus (HIV) to less than 1%; therefore, highly active antiretroviral therapy is used in all pregnant women regardless ...
L Iu Afonina, E E Voronin
doaj  

Abstracts From AIDS 2026, the 26th International AIDS Conference, 26 – 31 July 2026 Rio de Janeiro, Brazil & virtual

Journal of the International AIDS Society, Volume 29, Issue S4, July 2026.
wiley   +1 more source

Pharmacokinetics of darunavir/ritonavir in Asian HIV-1-infected children aged >/=7 years

, 2012
Item does not contain fulltextBACKGROUND: The Asian population, in general, has higher antiretroviral concentrations than those who are not Asian, but there are limited pharmacokinetic data for darunavir/ritonavir in Asian children.
Kerr, S.J., Tulathip Suwanlerk, Phongsamart, W., Nirun Vanprapar, Ananworanich, J., Burger, D.M., Jiratchiya Sophonphan, Prasitsuebsai, W., Chokephaibulkit, K., Sekar, V., Wittawatmongkol, O., Gorowara, M., Vanprapar, N., Wanatpreeya Phongsamart, Stephen J Kerr, Sophonphan, J., Thanyawee Puthanakit, Chayapa Pasomsap, Pasomsap, C., David Burger, Suwanlerk, T., Orasri Wittawatmongkol, Puthanakit, T., Kulkanya Chokephaibulkit, Wasana Prasitsuebsai, Jintanat Ananworanich, Meena Gorowara, Vanitha Sekar   +27 more
core   +1 more source

Site dependent intestinal absorption of darunavir and its interaction with ketoconazole

, 2013
The expression of P-gp increases from proximal to distal parts of the small intestine, whereas for P450 enzymes the expression is reported to be highest in duodenum and jejunum, decreasing to more distal sites.
Annaert, Pieter, Stappaerts, Jef, Augustijns, Patrick   +2 more
core   +1 more source

Análise quimico-farmacêutica de Darunavir etanolato em comprimidos e de seu complexo de inclusão

, 2015
The work aimed the formation of complex darunavir:β-cyclodextrin and the study of the consequences of complexation, as well as development and validation of analytical methods for qualitative and quantitative determination of darunavir in tablet (free ...
Kogawa, Ana Carolina
core   +2 more sources

Pharmacokinetics and Safety of Darunavir/Ritonavir in HIV-Infected Pregnant Women

, 2017
Item does not contain fulltextThe dosage of darunavir/ritonavir is 800/100 mg once daily for treatment-naive patients or treatment-experienced patients with no prior darunavir resistance associated mutations, and 600/100 mg twice daily for treatment ...
Burger, D.M., Peytavin, G., Moecklinghoff, C., Hadacek, M.B., Khoo, S., Hill, A., Brown, K., Porte, C. La   +7 more
core  

Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection

HIV/AIDS: Research and Palliative Care, 2016
Rustin D Crutchley,1 Rakesh C Guduru,2 Amy M Cheng1 1Department of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston, 2CompanionDX, Houston, TX, USA Abstract: Atazanavir/cobicistat (ATV/c) and darunavir/cobicistat (
Crutchley RD, Guduru RC, Cheng AM,
doaj  

Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study

Drug Design, Development and Therapy, 2019
A Antinori,1 S Rusconi,2 N Gianotti,3 T Bini,4 D Mancusi,5 R Termini51HIV/AIDS Department, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, Rome, Italy; 2Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan,
Antinori A, Rusconi S, Gianotti N, Bini T, Mancusi D, Termini R   +5 more
doaj  

Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir [PDF]

Reactions Weekly, 2020
openaire   +1 more source